Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.

Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM.

Am J Hematol. 2016 Aug;91(8):819-23. doi: 10.1002/ajh.24419. Epub 2016 Jun 30.

2.

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM.

Cancer. 2014 Dec 1;120(23):3660-8. doi: 10.1002/cncr.28930. Epub 2014 Jul 17.

3.

Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.

El-Cheikh J, El Dika I, Massoud R, Charafeddine M, Mahfouz R, Kharfan-Dabaja MA, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):179-185. doi: 10.1016/j.clml.2016.11.002. Epub 2016 Nov 21.

PMID:
27988194
4.

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ.

Cancer. 2004 Dec 15;101(12):2788-801.

5.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM.

J Clin Oncol. 2010 Aug 20;28(24):3880-9. doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26.

6.

Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Guzauskas GF, Villa KF, Vanhove GF, Fisher VL, Veenstra DL.

J Adolesc Young Adult Oncol. 2017 Mar;6(1):53-61. doi: 10.1089/jayao.2016.0049. Epub 2016 Oct 25.

7.

Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.

Alacacioglu I, Medeni SS, Ozsan GH, Payzin B, Sevindik OG, Acar C, Katgi A, Ozdemirkan F, Piskin O, Ozcan MA, Undar B, Demirkan F.

Chemotherapy. 2014;60(4):219-23. doi: 10.1159/000375258. Epub 2015 Apr 3.

PMID:
25871894
9.

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.

Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H.

Cancer. 2010 Oct 1;116(19):4580-9. doi: 10.1002/cncr.25319.

11.

The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.

Alabdulwahab AS, Elsayed HG, Sherisher MA, Zeeneldin A, Alghamdi K, Elbjeirami WM.

Leuk Res. 2017 Sep;60:58-62. doi: 10.1016/j.leukres.2017.06.010. Epub 2017 Jun 28.

PMID:
28704720
13.

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z.

Leuk Lymphoma. 2000 Jan;36(3-4):263-73.

PMID:
10674898
14.

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.

O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H.

Cancer. 2008 Oct 15;113(8):2097-101. doi: 10.1002/cncr.23819.

15.

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ.

J Clin Oncol. 2000 Feb;18(3):547-61.

PMID:
10653870
16.

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S.

Haematologica. 2015 May;100(5):653-61. doi: 10.3324/haematol.2014.118588. Epub 2015 Feb 14.

17.

Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.

Portugal RD, Loureiro MM, Garnica M, Pulcheri W, Nucci M.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):52-7. doi: 10.1016/j.clml.2014.03.004. Epub 2014 Jun 12.

PMID:
25037887
18.

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.

Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):54-9. doi: 10.3816/CLML.2011.n.007.

PMID:
21454191
19.

[Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].

Ramos-Peñafiel CO, Cabrera-García Á, Rozen-Fuller E, González-León G, Balderas C, Kassack-Ipiña JJ, Castellanos-Sinco H, Martínez-Murillo C, Montaño-Figueroa E, Martínez-Tovar A, Olarte-Carrillo I, Santoyo-Sánchez A, Collazo-Jaloma J.

Rev Peru Med Exp Salud Publica. 2014 Jul-Sep;31(3):525-9. Spanish.

20.

Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.

Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.

Acta Haematol. 2013;130(3):199-205. doi: 10.1159/000351172. Epub 2013 Jun 19.

PMID:
23797290

Supplemental Content

Support Center